XML 25 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
 3 Months Ended
Mar. 31, 2012
Mar. 26, 2011
Revenues:    
Net product revenues $ 24,654,794 $ 32,920,991
Research and development revenues 592,691 2,013,501
Revenues, Total 25,247,485 34,934,492
Expenses:    
Cost of product revenues 17,398,279 21,946,612
Research and development 5,128,996 6,384,749
Selling, general and administration 5,097,707 4,445,146
Costs and Expenses, Total 27,624,982 32,776,507
(Loss) income from operations (2,377,497) 2,157,985
Other income and expense:    
Interest income 233,555 263,692
Other income (expense), net 52,780 (33,557)
Foreign currency transaction losses (198,344) (290,959)
Gain on sale of investments 856,170  
Gain on sale of patents   155,658
Nonoperating Income (Expense), Total 944,161 94,834
Loss (income) before provision for income taxes, equity loss in unconsolidated affiliate and net (income) loss of noncontrolling interest (1,433,336) 2,252,819
Tax provision (468,000) (98,000)
(Loss) income before equity loss in unconsolidated affiliate and net (income) loss of noncontrolling interest (1,901,336) 2,154,819
Equity loss in unconsolidated affiliate (156,295) (110,639)
Net (loss) income (2,057,631) 2,044,180
Net (income) loss attributable to the noncontrolling interest (151,582) 21,527
Net (loss) income attributable to the controlling interest $ (2,209,213) $ 2,065,707
Net (loss) income per share    
Basic $ (0.03) $ 0.03
Diluted $ (0.03) $ 0.03
Weighted average number of common shares outstanding    
Basic 64,225,456 64,736,842
Diluted 64,225,456 65,655,074